Cooperation SeekingCreative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Cetuximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
Cetuximab binds to epidermal growth factor receptor (EGFr) on both normal and tumor cells and is widely used to treat metastatic CRC. EGFr is overexpressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGFα, thereby reducing their effect on cell growth and metastasis. Mouse model experiments show that cetuximab can target tumor cells through antibody-dependent cell-mediated cytotoxicity (ADCC) and increase antitumor activity.
Cetuximab is used in combination with irinotecan, and is suitable for the treatment of metastatic colorectal cancer expressing EGFR in patients who are difficult to treat with irinotecan-based chemotherapy. Cetuximab monotherapy can be used to treat metastatic colorectal cancer expressing EGFR in patients who are intolerant to irinotecan-based chemotherapy.
All products and services are for Research Use Only. Do Not use in humans.
Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.